Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGKA | P23743 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.33 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | EPHX2 | P34913 | 5/20 | 0.32 |
| ▸ | USP2 | O75604 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14570439 | 0.89 | DGKA (0.40) | DGKAALDH1A1TDP1MAPTCYP3A4 | |
| SCHEMBL9152252 | 0.88 | TSHR (0.35) | ALDH1A1TSHRKMT2A | |
| SCHEMBL14038139 | 0.86 | DGKA (0.42) | DGKACYP1A2ALDH1A1ALOX15TDP1 | |
| SCHEMBL16328978 | 0.85 | — | — | |
| SCHEMBL19008194 | 0.85 | MEN1 (0.35) | KMT2AGAAMEN1 | |
| SCHEMBL5597403 | 0.85 | ALDH1A1 (0.39) | CYP1A2ALDH1A1ALOX15TDP1MAPT | |
| SCHEMBL1501122 | 0.85 | ALDH1A1 (0.39) | CYP1A2ALDH1A1ALOX15TDP1MAPT | |
| SCHEMBL17099774 | 0.84 | DGKA (0.34) | DGKACYP1A2ALDH1A1ALOX15TDP1 | |
| SCHEMBL13675273 | 0.83 | — | — | |
| SCHEMBL13073086 | 0.81 | MCL1 (0.32) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-4731781-B2 | — | — | 2011-07-27 | — | — | JP | claimed |
| US-7833715-B1 | Biomolecules having multiple attachment moieties for binding to a substrate surface | NANOGEN RECOGNOMICS GMBH (DE) | 2010-11-16 | — | — | US | claimed |
| US-20100286377-A1 | BIOMOLECULES HAVING MULTIPLE ATTACHMENT MOIETIES FOR BINDING TO A SUBSTRATE SURFACE | NANOGEN RECOGNOMICS GMBH | 2010-11-11 | — | — | US | claimed |
| EP-1257695-B1 | BIOMOLECULES HAVING MULTIPLE ATTACHMENT MOIETIES FOR BINDING TO A SUBSTRATE SURFACE | NANOGEN RECOGNOMICS GMBH (DE) | 2007-03-07 | — | — | EP | claimed |
| EP-1257695-A4 | BIOMOLECULES HAVING MULTIPLE ATTACHMENT MOIETIES FOR BINDING TO A SUBSTRATE SURFACE | NANOGEN RECOGNOMICS GMBH (DE) | 2005-03-02 | — | — | EP | claimed |
| JP-2003521680-A | — | — | 2003-07-15 | — | — | JP | claimed |
| EP-1257695-A1 | BIOMOLECULES HAVING MULTIPLE ATTACHMENT MOIETIES FOR BINDING TO A SUBSTRATE SURFACE | Nanogen Recognomics GmbH (DE) | 2002-11-20 | — | — | EP | claimed |
| WO-2001051689-A1 | BIOMOLECULES HAVING MULTIPLE ATTACHMENT MOIETIES FOR BINDING TO A SUBSTRATE SURFACE | NANOGEN RECOGNOMICS GMBH (DE) | 2001-07-19 | — | — | WO | claimed |
| WO-2022115799-A1 | RADIOPHARMACEUTICAL CONJUGATES TARGETING GUANYLYL CYCLASE C, AND COMPOSITIONS AND USES THEREOF | RAYZEBIO, INC. (US) | 2022-06-02 | — | — | WO | disclosed |
| US-8067581-B2 | Biomolecules having multiple attachment moieties for binding to a substrate surface | SANOFI-AVENTIS S.A. (DE) | 2011-11-29 | — | — | US | disclosed |
| US-20110201080-A1 | BIOMOLECULES HAVING MULTIPLE ATTACHMENT MOIETIES FOR BINDING TO A SUBSTRATE SURFACE | SANOFI-AVENTIS S.A. (FR) | 2011-08-18 | — | — | US | disclosed |
| US-7833715-B1 | Biomolecules having multiple attachment moieties for binding to a substrate surface | NANOGEN RECOGNOMICS GMBH (DE) | 2010-11-16 | — | — | US | disclosed |
| US-7833715-B1 | Biomolecules having multiple attachment moieties for binding to a substrate surface | NANOGEN RECOGNOMICS GMBH (DE) | 2010-11-16 | — | — | US | disclosed |
| US-20100286377-A1 | BIOMOLECULES HAVING MULTIPLE ATTACHMENT MOIETIES FOR BINDING TO A SUBSTRATE SURFACE | NANOGEN RECOGNOMICS GMBH | 2010-11-11 | — | — | US | disclosed |
| EP-1309730-B1 | NEW HYDRAZIDE BUILDING BLOCKS AND HYDRAZIDE MODIFIED BIOMOLECULES | NANOGEN RECOGNOMICS GMBH (DE) | 2008-11-26 | — | — | EP | disclosed |
| EP-1309730-B1 | NEW HYDRAZIDE BUILDING BLOCKS AND HYDRAZIDE MODIFIED BIOMOLECULES | NANOGEN RECOGNOMICS GMBH (DE) | 2008-11-26 | — | — | EP | disclosed |
| EP-1257695-B1 | BIOMOLECULES HAVING MULTIPLE ATTACHMENT MOIETIES FOR BINDING TO A SUBSTRATE SURFACE | NANOGEN RECOGNOMICS GMBH (DE) | 2007-03-07 | — | — | EP | disclosed |
| EP-1257695-B1 | BIOMOLECULES HAVING MULTIPLE ATTACHMENT MOIETIES FOR BINDING TO A SUBSTRATE SURFACE | NANOGEN RECOGNOMICS GMBH (DE) | 2007-03-07 | — | — | EP | disclosed |
| US-7186813-B1 | Biomolecules having multiple attachment moieties for binding to a substrate surface | NANOGEN RECOGNOMICS GMBH (DE) | 2007-03-06 | — | — | US | disclosed |
| US-7129229-B2 | Hydrazide building blocks and hydrazide modified biomolecules | NANOGEN RECOGNOMICS GMBH (DE) | 2006-10-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110201080-A1 | BIOMOLECULES HAVING MULTIPLE ATTACHMENT MOIETIES FOR BINDING TO A SUBSTRATE SURFACE | RNGTT, PNKP, MTAP | DGKA 2860/4885CYP1A2 4751/4885ALDH1A1 3680/4885 |
| US-20100286377-A1 | BIOMOLECULES HAVING MULTIPLE ATTACHMENT MOIETIES FOR BINDING TO A SUBSTRATE SURFACE | SSB, EPCAM, BPGM | DGKA 4382/4885CYP1A2 4492/4885ALDH1A1 1344/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.